Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]

被引:0
|
作者
Fu, Liang [1 ]
Xiong, Juan [2 ]
Wang, Haibo [3 ]
Zhang, Peize [1 ]
Yang, Qianting [1 ]
Cai, Yi [4 ]
Wang, Wenfei [1 ,4 ]
Sun, Feng [5 ]
Zhang, Xilin [6 ]
Wang, Zhaoqin [1 ]
Chen, Xinchun [4 ]
Zhang, Wenhong [5 ]
Deng, Guofang [1 ]
机构
[1] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis Shenzhen, Div Pulm Dis Dept 2,Shenzhen Clin Res Ctr TB, 29 Bulan Rd, Shenzhen 518112, Peoples R China
[2] Shenzhen Univ, Hlth Sci Ctr, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China
[3] Peking Univ First Hosp, Peking Univ Clin Res Inst, Xueyuan Rd 38, Beijing 100191, Peoples R China
[4] Shenzhen Univ, Dept Pathogen Biol, Guangdong Key Lab Reg Immun & Dis, Sch Med, 1066 Xueyuan Ave, Shenzhen 518060, Peoples R China
[5] Fudan Univ, Huashan Hosp, Natl Med Ctr Infect Dis, Dept Infect Dis,Shanghai Key Lab Infectious Dis &, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China
[6] Fourth Peoples Hosp Foshan, TB Prevent & Control Dept, 106 Jinlannan Rd, Foshan 528000, Peoples R China
关键词
Multidrug-resistant; Tuberculosis; Efficacy; Safety; Trial; OUTCOMES;
D O I
10.1186/s12879-023-08644-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
IntroductionThe urgent need for new treatments for multidrug-resistant tuberculosis (MDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the classic randomized controlled trial (RCT) approach faces ethical and practical constraints, making alternative research designs and treatment strategies necessary, such as single-arm trials and host-directed therapies (HDTs).MethodsOur study adopts a randomized withdrawal trial design for MDR-TB to maximize resource allocation and better mimic real-world conditions. Patients' treatment regimens are initially based on drug resistance profiles and patient's preference, and later, treatment-responsive cases are randomized to different treatment durations. Alongside, a single-arm trial is being conducted to evaluate the potential of sulfasalazine (SASP) as an HDT for pre-XDR-TB, as well as another short-course regimen without HDT for pre-XDR-TB. Both approaches account for the limitations in second-line anti-TB drug resistance testing in various regions.DiscussionAlthough our study designs may lack the internal validity commonly associated with RCTs, they offer advantages in external validity, feasibility, and ethical appropriateness. These designs align with real-world clinical settings and also open doors for exploring alternative treatments like SASP for tackling drug-resistant TB forms. Ultimately, our research aims to strike a balance between scientific rigor and practical utility, offering valuable insights into treating MDR-TB and pre-XDR-TB in a challenging global health landscape. In summary, our study employs innovative trial designs and treatment strategies to address the complexities of treating drug-resistant TB, fulfilling a critical gap between ideal clinical trials and the reality of constrained resources and ethical considerations.Trail registrationChictr.org.cn, ChiCTR2100045930. Registered on April 29, 2021.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial
    Frye, Bjoern C.
    Rump, Ina Caroline
    Uhlmann, Annette
    Schubach, Fabian
    Ihorst, Gabriele
    Grimbacher, Bodo
    Zissel, Gernot
    Quernheim, Joachim Mueller
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
  • [22] Efficacy and Safety of Dapsone in Primary Immune Thrombocytopenia. Results of a Randomized, Placebo-Controlled Multicenter Trial and of a Single-Arm, Emulated Trial in the Prospective, Multicenter Carmen-France Registry
    Larue, Marion
    Moulis, Guillaume
    Rueter, Manuela
    Audia, Sylvain
    Terriou, Louis
    Viallard, Jean-Francois
    Petesch, Brigitte Pan
    Royer, Bruno
    Bonnotte, Bernard
    Galicier, Lionel
    Lambotte, Olivier
    Lefrere, Francois
    Cheze, Stephane
    Ebbo, Mikael
    Wagner-Ballon, Orianne
    Mahevas, Matthieu
    Godeau, Bertrand
    Michel, Marc
    BLOOD, 2023, 142
  • [23] Study Protocol of a Multicenter, Randomized, Single-Blind Trial: Efficacy and Safety of Remimazolam Tosylate for Sedation in ICU Patients
    Liu, Ning
    Jiang, Zhiyi
    Nie, Yao
    Zuo, Lingyun
    Chen, Chuanxi
    Si, Xiang
    Liu, Qin
    Chen, Minying
    Guan, Xiangdong
    ADVANCES IN THERAPY, 2023, 40 (05) : 2524 - 2533
  • [24] Study Protocol of a Multicenter, Randomized, Single-Blind Trial: Efficacy and Safety of Remimazolam Tosylate for Sedation in ICU Patients
    Ning Liu
    Zhiyi Jiang
    Yao Nie
    Lingyun Zuo
    Chuanxi Chen
    Xiang Si
    Qin Liu
    Minying Chen
    Xiangdong Guan
    Advances in Therapy, 2023, 40 : 2524 - 2533
  • [25] Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial
    Zhang, Shao-yan
    Qiu, Lei
    Zhang, Shun-xian
    Xiao, He-ping
    Chu, Nai-hui
    Zhang, Xia
    Zhang, Hui-qiang
    Zheng, Pei-yong
    Zhang, Hui-yong
    Lu, Zhen-hui
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2024, 30 (07) : 579 - 587
  • [26] Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania
    Stellah G. Mpagama
    Happiness C. Mvungi
    Peter M. Mbelele
    Hadija H. Semvua
    Alphonce A. Liyoyo
    Kristen Petros de Guex
    Derek Sloan
    Gibson S. Kibiki
    Martin Boeree
    Patrick P. J. Phillips
    Scott K. Heysell
    Pilot and Feasibility Studies, 9
  • [27] Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial
    ZHANG Shaoyan
    QIU Lei
    ZHANG Shunxian
    XIAO Heping
    CHU Naihui
    ZHANG Xia
    ZHANG Huiqiang
    ZHENG Peiyong
    ZHANG Huiyong
    LU Zhenhui
    Chinese Journal of Integrative Medicine, 2024, (07) : 579 - 587
  • [28] Efficacy and Safety of Bufei Jiedu Granules in Treating Multidrug-Resistant Pulmonary Tuberculosis: A Multi-center, Double-Blinded and Randomized Controlled Trial
    ZHANG Shaoyan
    QIU Lei
    ZHANG Shunxian
    XIAO Heping
    CHU Naihui
    ZHANG Xia
    ZHANG Huiqiang
    ZHENG Peiyong
    ZHANG Huiyong
    LU Zhenhui
    Chinese Journal of Integrative Medicine, 2024, 30 (07) : 579 - 587
  • [29] Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
    Mahamadou Bassirou Souleymane
    Tom Decroo
    Alphazazi Soumana
    Ibrahim Maman Lawan
    Assiatou Gagara-Issoufou
    Souleymane Halidou-Moussa
    Nimer Ortuño-Gutiérrez
    Eric Adehossi
    Saïdou Mamadou
    Armand Van Deun
    Alberto Piubello
    Trials, 23
  • [30] Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania
    Mpagama, Stellah G. G.
    Mvungi, Happiness C. C.
    Mbelele, Peter M. M.
    Semvua, Hadija H. H.
    Liyoyo, Alphonce A. A.
    de Guex, Kristen Petros
    Sloan, Derek
    Kibiki, Gibson S. S.
    Boeree, Martin
    Phillips, Patrick P. J.
    Heysell, Scott K. K.
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)